Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | HTR6 | P50406 | 2/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | HTR1D | P28221 | 1/20 | 0.68 |
| ▸ | HTR1B | P28222 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | HTR1E | P28566 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14473032 | 1.00 | HTR2A (0.69) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL8246556 | 1.00 | HTR2A (0.69) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL22803428 | 1.00 | HTR2A (0.69) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL14472913 | 0.88 | HTR2A (0.66) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL15344197 | 0.88 | HTR2A (0.66) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL357990 | 0.85 | HTR2A (0.66) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL22851547 | 0.85 | HTR2A (0.71) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL14665073 | 0.85 | HTR2A (0.67) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL13947623 | 0.85 | HTR2A (0.71) | HTR2AHTR1AHTR6ADRB1ADRA2A | |
| SCHEMBL1911320 | 0.85 | HTR2A (0.66) | HTR2AHTR1AHTR6ADRB1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578101-B2 | Proteasome inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-11357873-B2 | Chiral cyclen compounds and their uses | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR SA (ES) | 2022-06-02 | — | — | US | disclosed |
| WO-2021217019-A1 | RAS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-09-16 | — | — | US | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021011481-A1 | ANTI-INFLAMMATORY FACTORS | THE GENERAL HOSPITAL CORPORATION (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| EP-2928902-B1 | CONJUGATE COMPOUNDS | VICTORIA LINK LTD (NZ) | 2019-07-17 | — | — | EP | disclosed |
| US-10280229-B2 | Linkers and their application towards ADC | MEDSHINE DISCOVERY INC. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
| US-8633160-B2 | Small molecule inhibitors of PDZ interactions | NONO INC. (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20120251559-A1 | Treatment of B-Cell Cancers With Anti-CD70 Antibody-Drug Conjugates | SEATTLE GENETICS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100183636-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | SEATTLE GENETICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-0722321-A4 | SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS | UNIV FLORIDA STATE (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0722321-A1 | SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS | FLORIDA STATE UNIVERSITY (US) | 1996-07-24 | — | — | EP | disclosed |
| WO-1995009620-A1 | SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS | FLORIDA STATE UNIVERSITY (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0547178-A4 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER LAMBERT CO (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0547178-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578101-B2 | Proteasome inhibitors | PSMG3, PSME1, PSMB1 | HTR2A 4346/4885HTR1A 4324/4885HTR6 4052/4885 |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | CD79B, OGFR, CD2 | HTR2A 3395/4885HTR1A 1769/4885HTR6 3705/4885 |
| US-20100183636-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | CD74, CD63, CD2 | HTR2A 3514/4885HTR1A 4009/4885HTR6 2948/4885 |
| US-11357873-B2 | Chiral cyclen compounds and their uses | DCTN3, DCTN1, CDK3 | HTR2A 1326/4885HTR1A 1718/4885HTR6 4667/4885 |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | DCTN3, DCTN1, CDK3 | HTR2A 1326/4885HTR1A 1718/4885HTR6 4667/4885 |
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HTR2A 3011/4885HTR1A 2509/4885HTR6 2098/4885 |
| US-20120251559-A1 | Treatment of B-Cell Cancers With Anti-CD70 Antibody-Drug Conjugates | CD22, CD79B, CD74 | HTR2A 3972/4885HTR1A 4466/4885HTR6 3668/4885 |
| US-10280229-B2 | Linkers and their application towards ADC | DNPEP, DPP7, DPP3 | HTR2A 4571/4885HTR1A 4462/4885HTR6 4137/4885 |
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | CD47, MCL1, BCL9 | HTR2A 4204/4885HTR1A 4377/4885HTR6 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.